SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Chang BK, Timmerman RD. Stereotactic body radiation therapy: a comprehensive review. Am J Clin Oncol. 2007; 30: 637-644.
  • 2
    Martin A, Gaya A. Stereotactic body radiotherapy: a review. Clin Oncol (R Coll Radiol). 2010; 22: 157-172.
  • 3
    Lax I, Blomgren H, Naslund I, Svanstrom R. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol. 1994; 33: 677-683.
  • 4
    Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010; 303: 1070-1076.
  • 5
    Gerszten PC, Burton SA, Ozhasoglu C, Welch WC. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine (Phila Pa 1976). 2007; 32: 193-199.
  • 6
    Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009; 27: 1572-1578.
  • 7
    Nagata Y, Hiraoka M, Mizowaki T, et al. Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. Int J Radiat Oncol Biol Phys. 2009; 75: 343-347.
  • 8
    Beitler JJ, Badine EA, El-Sayah D, et al. Stereotactic body radiation therapy for nonmetastatic lung cancer: an analysis of 75 patients treated over 5 years. Int J Radiat Oncol Biol Phys. 2006; 65: 100-106.
  • 9
    Bradley JD, El Naqa I, Drzymala RE, Trovo M, Jones G, Denning MD. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant. Int J Radiat Oncol Biol Phys. 2010; 77: 1146-1150.
  • 10
    Chang JY, Balter PA, Dong L, et al. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008; 72: 967-971.
  • 11
    Coon D, Gokhale AS, Burton SA, Heron DE, Ozhasoglu C, Christie N. Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning. Clin Lung Cancer. 2008; 9: 217-221.
  • 12
    Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008; 70: 685-692.
  • 13
    Nagata Y, Negoro Y, Aoki T, et al. Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for 1 or 2 lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2002; 52: 1041-1046.
  • 14
    Takeda A, Sanuki N, Kunieda E, et al. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in 5 fractions to the periphery of the planning target volume calculated using a superposition algorithm. Int J Radiat Oncol Biol Phys. 2009; 73: 442-448.
  • 15
    Uematsu M, Shioda A, Suda A, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys. 2001; 51: 666-670.
  • 16
    Videtic GM, Stephans K, Reddy C, et al. Intensity-modulated radiotherapy-based stereotactic body radiotherapy for medically inoperable early-stage lung cancer: excellent local control. Int J Radiat Oncol Biol Phys. 2010; 77: 344-349.
  • 17
    Chang EL, Shiu AS, Mendel E, et al. Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J Neurosurg Spine. 2007; 7: 151-160.
  • 18
    Degen JW, Gagnon GJ, Voyadzis JM, et al. CyberKnife stereotactic radiosurgical treatment of spinal tumors for pain control and quality of life. J Neurosurg Spine. 2005; 2: 540-549.
  • 19
    Nelson JW, Yoo DS, Sampson JH, et al. Stereotactic body radiotherapy for lesions of the spine and paraspinal regions. Int J Radiat Oncol Biol Phys. 2009; 73: 1369-1375.
  • 20
    Sahgal A, Ames C, Chou D, et al. Stereotactic body radiotherapy is effective salvage therapy for patients with prior radiation of spinal metastases. Int J Radiat Oncol Biol Phys. 2009; 74: 723-731.
  • 21
    Yamada Y, Bilsky MH, Lovelock DM, et al. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys. 2008; 71: 484-490.
  • 22
    Cardenes HR, Price TR, Perkins SM, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol. 2010; 12: 218-225.
  • 23
    Choi BO, Choi IB, Jang HS, et al. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer. 2008; 8: 351.
  • 24
    Herfarth KK, Debus J, Lohr F, et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol. 2001; 19: 164-170.
  • 25
    Hoyer M, Roed H, Traberg Hansen A, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006; 45: 823-830.
  • 26
    McCammon R, Schefter TE, Gaspar LE, Zaemisch R, Gravdahl D, Kavanagh B. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2009; 73: 112-118.
  • 27
    Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2008; 26: 657-664.
  • 28
    Wulf J, Guckenberger M, Haedinger U, et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol. 2006; 45: 838-847.
  • 29
    Chang DT, Schellenberg D, Shen J, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009; 115: 665-672.
  • 30
    Koong AC, Christofferson E, Le QT, et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2005; 63: 320-323.
  • 31
    Koong AC, Le QT, Ho A, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004; 58: 1017-1021.
  • 32
    Schellenberg D, Goodman KA, Lee F, et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2008; 72: 678-686.
  • 33
    Beitler JJ, Makara D, Silverman P, Lederman G. Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma. Am J Clin Oncol. 2004; 27: 646-648.
  • 34
    Chawla S, Chen Y, Katz AW, et al. Stereotactic body radiotherapy for treatment of adrenal metastases. Int J Radiat Oncol Biol Phys. 2009; 75: 71-75.
  • 35
    Svedman C, Karlsson K, Rutkowska E, et al. Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol. 2008; 47: 1578-1583.
  • 36
    Wersall PJ, Blomgren H, Lax I, et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol. 2005; 77: 88-95.
  • 37
    Friedland JL, Freeman DE, Masterson-McGary ME, Spellberg DM. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat. 2009; 8: 387-392.
  • 38
    Fuller DB, Naitoh J, Lee C, Hardy S, Jin H. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys. 2008; 70: 1588-1597.
  • 39
    Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol. 2010; 10: 1.
  • 40
    King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC Jr. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2009; 73: 1043-1048.
  • 41
    Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007; 67: 1099-1105.
  • 42
    Buyyounouski MK, Price RA Jr, Harris EE, et al. Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys. 2010; 76: 1297-1304.
  • 43
    Simpson DR, Lawson JD, Nath SK, Rose BS, Mundt AJ, Mell LK. Utilization of advanced imaging technologies for target delineation in radiation oncology. J Am Coll Radiol. 2009; 6: 876-883.
  • 44
    Simpson DR, Lawson JD, Nath SK, Rose BS, Mundt AJ, Mell LK. A survey of image-guided radiation therapy use in the United States. Cancer. 2010; 116: 3953-3960.
  • 45
    Jiang SB, Wolfgang J, Mageras GS. Quality assurance challenges for motion-adaptive radiation therapy: gating, breath holding, and four-dimensional computed tomography. Int J Radiat Oncol Biol Phys. 2008; 71:( 1 suppl): S103-S107.
  • 46
    Keall PJ, Mageras GS, Balter JM, et al. The management of respiratory motion in radiation oncology report of AAPM Task Group 76. Med Phys. 2006; 33: 3874-3900.
  • 47
    Keall PJ, Kini VR, Vedam SS, Mohan R. Potential radiotherapy improvements with respiratory gating. Australas Phys Eng Sci Med. 2002; 25: 1-6.
  • 48
    De La Fuente Herman T, Vlachaki MT, Herman TS, Hibbitts K, Stoner JA, Ahmad S. Stereotactic body radiation therapy (SBRT) and respiratory gating in lung cancer: dosimetric and radiobiological considerations. J Appl Clin Med Phys. 2010; 11: 3133.
  • 49
    Negoro Y, Nagata Y, Aoki T, et al. The effectiveness of an immobilization device in conformal radiotherapy for lung tumor: reduction of respiratory tumor movement and evaluation of the daily setup accuracy. Int J Radiat Oncol Biol Phys. 2001; 50: 889-898.
  • 50
    Wunderink W, Mendez Romero A, de Kruijf W, de Boer H, Levendag P, Heijmen B. Reduction of respiratory liver tumor motion by abdominal compression in stereotactic body frame, analyzed by tracking fiducial markers implanted in liver. Int J Radiat Oncol Biol Phys. 2008; 71: 907-915.
  • 51
    Gagel B, Demirel C, Kientopf A, et al. Active breathing control (ABC): determination and reduction of breathing-induced organ motion in the chest. Int J Radiat Oncol Biol Phys. 2007; 67: 742-749.
  • 52
    D'Souza WD, Naqvi SA, Yu CX. Real-time intra-fraction-motion tracking using the treatment couch: a feasibility study. Phys Med Biol. 2005; 50: 4021-4033.
  • 53
    Sawant A, Venkat R, Srivastava V, et al. Management of three-dimensional intrafraction motion through real-time DMLC tracking. Med Phys. 2008; 35: 2050-2061.